2019-02-12
OssDsign AB raises 64 MSEK (6 MEUR) through private placement and initiates preparations for stock exchange listing
Uppsala, Sweden 2019-02-12|OssDsign AB, the Swedish designer, manufacturer and distributor of regenerative implants for improved healing of bone defects, today announced the closing of a private placement of 64 MSEK (6 MEUR). The financing was achieved through a combination of Swedish private investors and the French investment management company Alto Invest. OssDsign will now also initiate the process towards a stock exchange listing during 2019.
2018-10-29
Retrospective study featuring OSSDSIGN® Cranial published in World Neurosurgery
Uppsala, Sweden 2018-10-29 | OssDsign AB, the Swedish designer, manufacturer and distributor of regenerative implants for cranial and facial reconstruction, today announced positive results from a retrospective study of OSSDSIGN® Cranial PSI that has been accepted for publication in World Neurosurgery.
2018-10-22
OssDsign announces FDA 510(k) clearance of OSSDSIGN® Cranioplug – designed with a ceramic material component that resorbs and is replaced with bone during the healing process
Uppsala, Sweden 2018-10-22 | OssDsign AB, the Swedish designer, manufacturer and distributor of regenerative implants for cranial and facial reconstruction, today announced that it has received 510(k) clearance by the US FDA for marketing and sale of its latest product, OSSDSIGN® Cranioplug.
2018-09-20
Major cranial reconstruction: Case report published in Journal of Neurosurgery
On September 14 th , the renowned Journal of Neurosurgery published a case report...
2018-03-05
Patient story with OSSDSIGN Cranial featured in Minnesota newspaper
A patient story using OSSDSIGN Cranial PSI is currently featured in the Minnesota...
2018-01-16
OssDsign accelerates commercial efforts in the US
Uppsala 2018-01-16 | OssDsign AB, a Swedish designer, manufacturer and distributor of next generation implants for cranial and facial reconstruction, today announced that it has established a US subsidiary and made initial key recruitments.
2017-11-02
MEET US AT THE 3RD ANNUAL SELECTED TOPICS IN CMF SURGERY
OSSDSIGN Cranial PSI is once again on display in Boston - this time at the third...
2017-09-08
Discover a new approach to cranioplasty at CNS in Boston
OSSDSIGN Cranial on display at CNS Annual Meeting in Boston, October 7-11.
2017-04-19
BRINGING LIFE TO CRANIOPLASTY
OSSDSIGN Cranial on display at the AANS in Los Angeles, April 22-26.
2017-02-02
OssDsign announces agreement for distribution of OSSDSIGN Cranial in the USA with Matador Medical Inc.
Uppsala 2/2/2017. OssDsign AB has signed an agreement with Matador Medical Inc. to act as its master distributor in the US market.
2017-01-20
OssDsign announces FDA 510(k) clearance of OSSDSIGN® Cranial for sale in the USA
Uppsala, Sweden 20/1/2017. OssDsign AB, a Swedish designer, manufacturer and distributor...
2016-04-20
OssDsign appoints Simon Cartmell as Chairman of the Board
Strengthens organization ahead of the US Launch of its Novel Regenerative Facial and Cranial Implants in 2017
2016-03-03
Meet OssDsign
We are looking forward to meet you at the following events during 2016.
2016-01-27
OssDsign receives CE mark approval for Cranioplug
OssDsign AB today announced that the company has received CE mark approval for its bio-ceramic burr hole plug - Cranioplug.
2016-01-16
Meet OssDsign during 2017
We are looking forward to meet you at the following events during 2017.
2015-11-04
OssDsign raises SEK 93 million (EUR 9.6 million) for commercial expansion
OssDsign AB today announced that it has successfully raised SEK 93 million (EUR 9.6 million), in a new equity financing.
2014-12-04
CRANIOPLASTY TODAY, ISSUE 1
In the News:
WHAT’S THE PROBLEM? - NATIONAL REGISTRIES AIM TO IMPROVE CRANIOPLASTY
In Depth
THE EVOLUTION OF CRANIAL IMPLANT MATERIALS - FROM REPAIR TOWARDS REGENERATION
2014-10-20
OSSDSIGN’S CRANIOPLUG RECEIVES MARKETING APPROVAL IN THE US
STOCKHOLM - October 20, 2014. OssDsign AB today announced that its bioceramic burr hole plug - Cranioplug - has received 510(k) clearance by the US Food and Drug Administration (FDA). Karolinska Development has a 26 percent ownership in OssDsign.
